Dihydroberberine (DHB) and some lipid-based berberine products produced higher blood levels of berberine than standard berberine in small studies of healthy adults, but no study we found shows that any one form lowers blood sugar better or is gentler on the gut. Standard berberine, usually sold as berberine hydrochloride (HCl), is poorly absorbed, which is the reason newer forms exist. The human studies of the newer forms involved between 5 and 10 people, gave a single dose or a few doses, and were funded by companies linked to the products. There is also no validated conversion between forms: no study tells you how many milligrams of DHB equal a given dose of standard berberine. People who take prescribed medicines should speak to a GP or pharmacist before choosing any berberine product.[1][2][3]
What the studies measured
Berberine concentrations in blood after a dose. None of the three human studies of newer forms that we reviewed measured long-term blood sugar outcomes.
Size of the evidence
DHB: 5 men. Lipid-micelle softgel: 10 adults. Liposomal: 6 men. All were single-site pilots in healthy people.
Evidence limitations
No trial compares forms for blood sugar, side effects or long-term safety. No dose equivalence exists between forms.
When to seek professional advice
Before use if you take prescribed medicines, are pregnant or breastfeeding, or have a medical condition (Food Standards Agency advice).
Why standard berberine has low bioavailability
Berberine is a yellow plant alkaloid, and most supplements contain it as the hydrochloride salt. Bioavailability means the share of a swallowed dose that actually reaches the bloodstream. For standard berberine that share is small. Researchers describe four hurdles: a pump in the gut wall called P-glycoprotein that pushes it back into the gut (like a bouncer turning most guests away at the door), breakdown by gut bacteria, heavy processing by the liver, and removal by the kidneys [4]. Each newer form tries to get past one or more of those hurdles.
Low blood levels do not by themselves mean a product is ineffective, and high blood levels do not by themselves mean it works better. Concentration in the blood is a pharmacokinetic measurement, meaning it describes where the substance goes and how fast. Whether that changes blood sugar, cholesterol or side effects is a separate question that needs a clinical trial. That distinction matters throughout this article, because every human study of a newer form that we found measured blood levels, and the two that also measured glucose found no difference [1][3].
Berberine HCl versus dihydroberberine (DHB)
What DHB is
Dihydroberberine is a chemically modified version of berberine, sold in supplements under the abbreviation DHB. The name tells you it is a close relative rather than a different plant compound, and the studies below measured the amount of berberine in blood after dosing it.
The only human comparison we could find
A 2022 pilot study in Nutrients tested five healthy, physically active men in a randomised, double-blind crossover design, which means each man took every condition in turn with a washout in between [1]. The conditions were placebo, 500 mg of standard berberine (at least 99% pure, from Berberis aristata), 100 mg of DHB and 200 mg of DHB. Participants took doses with meals the day before and a final dose after an overnight fast, followed by a test meal of 30 g of glucose with white bread. Blood was drawn over the next two hours [1].
Total berberine exposure over those two hours (the area under the curve, or AUC) was higher after both DHB doses than after the 500 mg standard dose. The authors report about 284 ng/mL×120 min for 100 mg of DHB and about 929 for 200 mg of DHB, against about 42 for 500 mg of standard berberine, with an overall significant effect of condition (p = 0.045) [1]. Peak concentration (Cmax) was about 3.8 ng/mL for 100 mg of DHB and about 0.40 ng/mL for 500 mg of standard berberine; only the lower DHB dose reached significance against standard berberine, while the 200 mg result was a trend, and the authors note that two high values in that group strongly influenced the data [1]. Think of AUC as the total water a wave carries past you and Cmax as the height of the wave.
Glucose and insulin responses to the test meal did not differ between conditions [1]. The authors state that the study was too small and short to draw efficacy conclusions, and the funder was the company that supplies the DHB ingredient, with one author a paid adviser to it [1].
What this does and does not tell you
It supports one narrow conclusion: in five healthy men, much smaller DHB doses produced higher berberine blood levels than a larger standard dose, over a two-hour window. It does not show that DHB lowers blood sugar better, that it is safer, or that results would be the same in women, older adults or people with type 2 diabetes.
Berberine phytosome and other enhanced forms
Is berberine phytosome really 10 times better absorbed?
A phytosome is a complex in which a plant compound is bound to phospholipids, the fatty molecules that make up cell membranes, with the aim of helping it cross the gut wall. We did not find a peer-reviewed human pharmacokinetic study of a branded berberine phytosome that we could open and check, so we cannot confirm the “10 times” figure repeated on many retail and blog pages. Our searches surfaced those pages, but marketing pages are not evidence.
The figure may come from a different product. A 2023 study of a lipid-based micellar softgel, which its authors describe as a micellar delivery system, not a phytosome, gave 10 healthy adults a single 500 mg dose of the softgel and of standard berberine HCl on separate occasions, fasted, with blood sampling over 24 hours [2]. Peak concentration was about 15.8 ng/mL after the softgel against 1.67 ng/mL after standard berberine, roughly 9.5 times higher, while total exposure (AUC) was about 5.8 times higher; the peak came at about one hour against about five and a half hours [2]. The study was not randomised, used a single dose, found no adverse events on health questionnaires, and was funded by the product’s manufacturer [2]. A “10-fold” headline is therefore a peak-concentration ratio from one small industry-funded study of a different product type.
Liposomal berberine
A 2026 randomised, double-blind crossover pilot gave six healthy men a single 400 mg dose of a liposomal product and of unformulated berberine powder [3]. Peak concentration was 70.1% higher and total exposure over 24 hours 42.8% higher with the liposomal form (both p = 0.03), but glucose and insulin over 24 hours did not differ, the study had no placebo arm, and the funder markets the product [3].
Why you cannot compare these studies with each other
It is tempting to line up the numbers and rank the forms, but the studies are not comparable. They used different doses (100 to 500 mg), different sampling windows (two hours in the DHB study, 24 hours in the others), different fasting and meal conditions, and different assay units. Even the standard berberine comparator behaved differently: its peak was about 0.40 ng/mL in the DHB study, which sampled for two hours, and 1.67 ng/mL in the softgel study, which sampled for 24 hours and recorded a peak at about five and a half hours [1][2]. A short sampling window can miss a late peak, so a form that peaks earlier may look better than it is. Only a study that gives all the forms to the same people under the same conditions could rank them, and we did not find one.
| Form | Study found | What was measured | What it does not show |
|---|---|---|---|
| Standard berberine (HCl) | Comparator in each study below | Lowest blood levels in each comparison | Not a safety or efficacy ranking |
| Dihydroberberine (DHB) | 5 healthy men; 100 or 200 mg vs 500 mg standard; randomised crossover [1] | Higher berberine AUC; no glucose difference | Glucose benefit, tolerability, long-term safety, women, people with diabetes |
| Lipid-micelle softgel | 10 healthy adults; 500 mg single dose; not randomised [2] | Cmax about 9.5 times and AUC about 5.8 times standard HCl | Glucose outcomes, repeat dosing, independent replication |
| Liposomal | 6 healthy men; 400 mg single dose; randomised crossover [3] | Cmax +70.1%, AUC +42.8%; no glucose or insulin difference | Efficacy, women, steady-state dosing |
| Phytosome (phospholipid complex) | No peer-reviewed human study we could open | Not assessed | Any absorption figure for this form |
Is dihydroberberine easier on the stomach?
We found no study that compared stomach side effects between forms. In the DHB pilot, 11 adverse events were recorded across all conditions: six with 100 mg of DHB (from two participants), three with placebo, one with 200 mg of DHB and one with standard berberine, most mild and most gastrointestinal or general in nature, but the authors say the numbers were too small to compare [1]. The softgel study reported no adverse events on health questionnaires in 10 people, and the liposomal paper states both forms were well tolerated without giving counts [2][3].
Stomach upset is the best-documented side effect of standard berberine. In the 2008 pilot trial of 500 mg three times daily, 34.5% of participants had transient gastrointestinal effects, mostly in the first four weeks, and the authors suggested, citing laboratory work, that berberine’s action on gut enzymes and sugar transport in the gut lining might contribute [9]. If that idea is right, a form built to be absorbed more efficiently would not necessarily reduce effects that arise in the gut itself. That is a theoretical explanation, not a tested result, and no trial has tested whether any form changes gut symptoms.
Dosage, equivalence and what the label says
There is no licensed UK dose of berberine, because supplements are regulated as food, and the Food Standards Agency advises following the label and not taking more than recommended [8]. The trials of glucose lowering that most people cite used standard berberine, for example 500 mg three times daily in the 2008 pilot [9]. The DHB study compared single 100 mg and 200 mg DHB doses against 500 mg of standard berberine on blood levels only [1].
How much DHB equals 1,500 mg of standard berberine?
The evidence does not allow an answer. Five men, one fasting dose and a two-hour sampling window cannot produce a conversion factor, and exposure ratios from a pilot study are not equivalent doses for blood sugar. A DHB label that states an equivalence to a larger standard dose is drawing on the manufacturer’s own assumptions. If you move between forms, follow each product’s label and speak to a pharmacist rather than converting milligrams yourself.
Safety, interactions and regulatory context
Speak to a GP or pharmacist before using any berberine product if any of these apply
- You take ciclosporin. In a randomised trial of 104 kidney-transplant recipients, standard berberine raised ciclosporin trough levels by 88.9% from baseline over three months [6].
- You take other prescribed medicines. In a randomised crossover study of healthy men taking 300 mg of standard berberine three times daily for two weeks, activity of the liver enzymes CYP2D6, CYP2C9 and CYP3A4 fell, with exposure to a CYP3A4 test drug (midazolam) about 40% higher [5]. EFSA’s draft assessment also reports possible CYP3A4 inhibition [7].
- You take diabetes medicines. Berberine lowers blood sugar in trials, so ask your diabetes team how it fits with your treatment.
- You are pregnant, breastfeeding or have a medical condition. The Food Standards Agency gives this advice for any supplement [8].
These are interaction and precaution points from studies of standard berberine. No study has tested whether DHB or enhanced-absorption forms change the size of these interactions, so we cannot say they are larger, smaller or the same.
A draft EFSA opinion in 2026 concluded that the data did not allow a safe intake to be established for berberine plant preparations; its stated scope was plant preparations, and we did not find it addressing dihydroberberine or branded formulations specifically [7]. That is a safety review rather than a ban, and we found no restriction on berberine supplements in Great Britain at the time of writing (5 November 2026). Check the Food Standards Agency website for updates.
Third-party testing is a sensible quality check for any supplement, because a label alone cannot confirm the amount of berberine in a capsule. None of the studies above checked whether commercial products match their labels.
Frequently asked questions
What is the difference between berberine HCl and dihydroberberine?
HCl is the salt form of standard berberine; dihydroberberine is a modified version. In the only human comparison we found, five men had higher blood berberine levels after small DHB doses than after a larger standard dose, with no difference in glucose [1].
What is the easiest form of berberine on the stomach?
No study has compared forms for stomach tolerance, so no form can be called easiest. The adverse event counts in the studies we reviewed were too small to compare [1][2][3].
What is the best form for someone with a sensitive gut?
The evidence cannot identify one. If berberine upsets your stomach, the Food Standards Agency advises stopping the supplement and contacting a healthcare professional rather than changing the dose yourself [8].
Editorial summary
The newer forms of berberine are built on a real problem, because standard berberine reaches the blood in small amounts. Small studies of DHB, a lipid-micelle softgel and a liposomal product each found higher berberine blood levels than the standard form they were compared with. What the studies did not do is show a benefit for blood sugar, show better stomach tolerance, or provide a conversion between forms. A phytosome has no human study that we could open and check.
For readers, the practical points are modest: higher blood levels are not proof of better results, the “10 times” style claims come from single small studies of specific products, and anyone taking prescribed medicines should check with a pharmacist before using any form. Independent, larger trials giving several forms to the same people, with glucose and tolerability outcomes, would change this picture. Evidence reviewed on 5 November 2026.
References
- Moon JM, Ratliff KM, Hagele AM, Stecker RA, Mumford PW, Kerksick CM. Absorption kinetics of berberine and dihydroberberine and their impact on glycemia: a randomized, controlled, crossover pilot trial. Nutrients. 2022;14(1):124. (Funded by the supplier of the dihydroberberine tested.) Full text (institutional repository)
- Characterization and pharmacokinetic assessment of a new berberine formulation with enhanced absorption in vitro and in human volunteers. (Industry-funded; authors include employees of the research organisation and holders of a related patent.) PubMed Central full text
- Liposomal delivery as a strategy to improve berberine bioavailability. Nutrition and Dietary Supplements. 2026. (Funded by the company that markets the liposomal product.) Full text (Dove Medical Press)
- Petrangolini G, et al. Development of an innovative berberine food-grade formulation with an ameliorated absorption: in vitro evidence confirmed by healthy human volunteers pharmacokinetic study. Evid Based Complement Alternat Med. 2021. (Authors are employees of the formulation developer.) Full text via DOI
- Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. DOI 10.1007/s00228-011-1108-2. Springer record
- Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567–572. PubMed record
- European Food Safety Authority. EFSA’s draft opinion on the safety of plant preparations containing berberine: stakeholder webinar slides, 22 April 2026. EFSA slides (PDF)
- Food Standards Agency. Food supplements guidance (consumers). GOV.UK, published 25 June 2026. GOV.UK guidance
- Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–717. PubMed record
Clinical & Regulatory Disclaimer
The content published on Vetted Therapeutics is provided for educational and informational purposes only. It does not constitute medical diagnosis, individualised treatment advice, clinical prescribing, or dietary recommendation. Information is based on available published research, nutritional and botanical monographs, and relevant regulatory guidance, subject to the limitations of the cited evidence. Vetted Therapeutics is an independent educational publisher and does not sell prescription medicines or endorse specific commercial healthcare brands. Articles are editorially independent; third-party links or advertisements do not influence our factual reviews or evaluations. Always consult a qualified healthcare professional, General Practitioner (GP), or pharmacist before starting, changing, or discontinuing any dietary supplement, botanical remedy, or prescription medication—particularly if you have pre-existing health conditions, take prescribed medicines, or are pregnant or breastfeeding. Food supplements must not be used as a substitute for a varied, balanced diet or medical care. For urgent medical concerns in the UK, contact NHS 111; in a life-threatening emergency, call 999.